The driver underneath the pharmacology

#Not vanity — a diagnosis

Nearly everything in the previous lesson is a technique someone chose to use. The choice itself has a documented psychiatric substrate that gets skipped almost everywhere this subject is discussed.

Muscle dysmorphia ("bigorexia") is a specific form of body dysmorphic disorder: a preoccupation with the belief that your body is insufficiently large or lean, regardless of how large or lean it actually is. It was first clinically described by Harvard Medical School researchers who remain the field's foundational authorities on it.

Reported prevalence is roughly 2–6% in general university-age men — but 13.6% to 44% among male weightlifters specifically, with competitive athletes carrying higher risk than non-competitive lifters. That is not a rounding difference. It means the population most likely to be reading this exact module is the population the condition concentrates in.

The published case report of a fatal DNP intoxication in the previous lesson names muscle dysmorphia directly in its own title, alongside the drug use that killed the patient. That is not a coincidence. The psychiatric condition and the pharmacological escalation are frequently the same story, told from two different departments of the same hospital.

#What this means practically

The demand for the practices in the previous lesson is frequently generated by a diagnosable, treatable condition — not by an accurate read of what a competitive physique actually requires. If the preoccupation described above sounds like your own thinking, the better next step is a conversation with a clinician, not a protocol on this page. See The Mind for the same evidence-first standard applied to cognition and connection more broadly.

#Retrieve

This closes the show-prep module. Nothing past this point in either program requires it — it exists for the specific decision to compete, and for no other reason.